Journal of Clinical Medicine (JCM) MDPI’s Post

📃Scientific paper: Management of the congenital solitary kidney: consensus recommendations of the Italian Society of Pediatric Nephrology Abstract: Background In recent years, several studies have been published on the prognosis of children with congenital solitary kidney (CSK), with controversial results, and a worldwide consensus on management and follow-up is lacking. In this consensus statement, the Italian Society of Pediatric Nephrology summarizes the current knowledge on CSK and presents recommendations for its management, including diagnostic approach, nutritional and lifestyle habits, and follow-up. Summary of the recommendations We recommend that any antenatal suspicion/diagnosis of CSK be confirmed by neonatal ultrasound (US), avoiding the routine use of further imaging if no other anomalies of kidney/urinary tract are detected. A CSK without additional abnormalities is expected to undergo compensatory enlargement, which should be assessed by US. We recommend that urinalysis, but not blood tests or genetic analysis, be routinely performed at diagnosis in infants and children showing compensatory enlargement of the CSK. Extrarenal malformations should be searched for, particularly genital tract malformations in females. An excessive protein and salt intake should be avoided, while sport participation should not be restricted. We recommend a lifelong follow-up, which should be tailored on risk stratification, as follows: low risk: CSK with compensatory enlargement, medium risk: CSK without compensatory enlargement and/or additional CAKUT, and high risk: decreased GFR and/or proteinuria, and/or hypertens... Continued on ES/IODE ➡️ https://etcse.fr/CE7 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Have you read the April issue of the Clinical Journal of the American Society of Nephrology (CJASN)? Check out this month’s collection to discover the latest advancements, research findings, industry trends, and more. Explore this month’s highlights: 🔸 Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial: https://bit.ly/3JxPD2I 🔸 Associations of Changes in Bone Turnover Markers with Change in Bone Mineral Density in Kidney Transplant Patients: https://bit.ly/3Ub6SvB 🔸 Patient-Centered Home Hemodialysis: Approaches and Prescription: https://bit.ly/3UtPmnH 🔸 How I Evaluate a High Anion Gap Metabolic Acidosis: https://bit.ly/3w5ANxa 🔸 Chronic Interstitial Nephritis in Agricultural Communities: Observational and Mechanistic Evidence Supporting the Role of Nephrotoxic Agrochemicals: https://bit.ly/3UfhyJs Read these articles and more: https://bit.ly/43tkRBm

Clinical Nephrology studies kidney function and diseases, including renal replacement therapy. Research in this field aims to improve the management of #kidneydisorders and develop new treatments. Stay updated on the latest findings to enhance patient care. #oriele #nephrology

For nephrology professionals and kidney disease patients: Our latest blog post explores lanthanum carbonate, its potential, and the ongoing debate about its long-term use. What are your thoughts? #TKE #kidneydisease #nephrology #phosphatebinder #hyperphosphatemia #research #healthcare https://lnkd.in/eNA7k7HR

As someone in the healthcare/kidney disease community, I'm always interested in the latest research on phosphate binders. The potential benefits and safety concerns with lanthanum carbonate are worth considering. Curious to hear others' experiences or insights. #kidneydisease #nephrology #phosphatebinder #hyperphosphatemia #research #healthcare

Long-term outcomes of rituximab-treated adult patients with podocytopathies This study found that rituximab facilitated achievement of initial and long-term response in a majority of adult patients with difficult-to-treat podocytopathies. Journal of the American Society of Nephrology ():10.1681/ASN.0000000520, October 16, 2024 DOI: 10.1681/ASN.0000000520

🔬 Dr. Ina Kacso, MD, PhD, is a distinguished Professor of Nephrology at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj, and serves as the Head of the Department of Nephrology at the Emergency County Hospital Cluj. Currently the President of the Romanian Society of Nephrology, Dr. Kacso specializes in glomerular diseases and the pathogenic mechanisms of chronic kidney disease (CKD), both diabetic and non-diabetic. Her expertise and leadership continue to advance the field of nephrology in Romania. #Nephrology #MedicalExcellence

An existing drug shows promise in preventing migraines before pain begins 🧠 New research suggests that AbbVie's Ubrelvy - already approved to treat migraines - may also prevent them when taken at the early warning signs. In a study published this week in the journal, Neurology, Ubrelvy was 73% more effective than a placebo in stopping migraines before they fully develop. Furthermore, the trial found that patients who took Ubrelvy during the prodrome stage (when first symptoms like fatigue, dizziness, and visual aura appear) were ‘not at all limited’ or ‘a little limited’ in their daily activity, compared to 48% of placebo recipients.  The drug has not yet been approved in the UK, but Ubrelvy’s ability to tackle symptoms at the early stages carves out a significant niche in a crowded market, offering the potential to pre-emptively relieve the debilitating pain experienced by millions. Read more about the trial results via the link in comments 👇 #MigraineRelief #PharmaNews #HealthcareInnovation #AbbVie #HlxLifeSciences

Did you miss Vicki Teodorescu's presentation at the recent AMERICAN SOCIETY OF DIAGNOSTIC & INTERVENTIONAL NEPHROLOGY annual scientific meeting (23–25 February 2024, New Orleans, USA) exploring the various options and comparative outcomes of materials used in #arteriovenousgrafts (AVGs)? If so, follow the link below to read our full article and learn more!

In a praise to Nephrology... Some days ago in a meeting, someone told me "I like your sticker!". I almost forgot about Kidney Lad stuck on my laptop together with ASN "United 4 Kidney Health" sticker but, Kidney Lad is a good reminder of the amazing work we have been doing for the last 3 years in General Medicine, now CVGM at PPD. Kidney Lad below was created by Sarah Dixon Stump, MS and her husband Michael Stump that I won't be able to thank enough for their creativity. I am often joking, saying that 6/7 years ago and more, talking about nephrology, perhaps 70% of people would understand "neurology" and the remaining 30% "phrenology", perhaps because there have historically been limited therapeutic options in CKD/DKD and the rarer glomerular diseases to substantially modify disease course, delaying time to ESRD and dialysis or kidney transplant. But everything changed in recent times and with the research conducted with Andy Bevan and Carmichael Angeles, MD MBA FASN, we showed how clinical development activities in nephrology greatly increased compared to the past, and the renewed interest by the pharma industry is fostering research, and approvals of drugs with new mechanism of actions and synergistic effects. We're in the middle of a revolution in this therapeutic area, which is further expanding its scope in a newer "cardiorenal-metabolic" space with the latest scientific literature published about the role of SGLT2is and GLP-1 in prevention. Thus, in this praise to nephrology, thanks to the scientific, medical and patients' community working on the different aspects of diseases characterization, research and treatment for their curiosity and passion. And Thank you, Kidney Lad!